Cronos Group Inc. (CRON)
USD 1.84
(-1.6%)
USD 1.84
(-1.6%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 88.84 Million USD | -3.33% |
| 2022 | 91.9 Million USD | 23.47% |
| 2021 | 74.43 Million USD | 59.32% |
| 2020 | 46.71 Million USD | 96.71% |
| 2019 | 23.75 Million CAD | 106.0% |
| 2018 | 11.52 Million CAD | 255.17% |
| 2017 | 3.24 Million CAD | 687.28% |
| 2016 | 412.32 Thousand CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 100.0% |
| 2013 | -195.61 Thousand CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 27.75 Million USD | 10.25% |
| 2024 Q1 | 25.17 Million USD | 2.44% |
| 2023 Q4 | 24.57 Million USD | -27.53% |
| 2023 Q2 | 19.02 Million USD | -5.57% |
| 2023 Q3 | 33.91 Million USD | 78.29% |
| 2023 Q1 | 20.14 Million USD | -11.98% |
| 2023 FY | 88.84 Million USD | -3.33% |
| 2022 Q4 | 22.88 Million USD | 9.39% |
| 2022 Q3 | 20.92 Million USD | -9.27% |
| 2022 Q2 | 23.06 Million USD | -7.88% |
| 2022 FY | 91.9 Million USD | 23.47% |
| 2022 Q1 | 25.03 Million USD | -2.95% |
| 2021 Q3 | 20.4 Million USD | 30.63% |
| 2021 Q4 | 25.79 Million USD | 26.4% |
| 2021 Q1 | 12.61 Million USD | -26.02% |
| 2021 FY | 74.43 Million USD | 59.32% |
| 2021 Q2 | 15.62 Million USD | 23.88% |
| 2020 Q1 | 8.43 Million USD | 15.38% |
| 2020 Q3 | 11.35 Million USD | 14.92% |
| 2020 Q4 | 17.04 Million USD | 50.08% |
| 2020 FY | 46.71 Million USD | 96.71% |
| 2020 Q2 | 9.88 Million USD | 17.21% |
| 2019 Q4 | 7.3 Million CAD | -23.82% |
| 2019 Q3 | 9.59 Million CAD | 23.03% |
| 2019 Q2 | 7.79 Million CAD | 60.92% |
| 2019 Q1 | 4.84 Million CAD | 30.52% |
| 2019 FY | 23.75 Million CAD | 106.0% |
| 2018 Q2 | 2.58 Million CAD | 13.16% |
| 2018 Q1 | 2.28 Million CAD | 81.89% |
| 2018 Q3 | 2.91 Million CAD | 12.77% |
| 2018 FY | 11.52 Million CAD | 255.17% |
| 2018 Q4 | 3.71 Million CAD | 27.57% |
| 2017 Q2 | 494.94 Thousand CAD | 28.47% |
| 2017 FY | 3.24 Million CAD | 687.28% |
| 2017 Q4 | 1.25 Million CAD | 18.36% |
| 2017 Q3 | 1.05 Million CAD | 114.03% |
| 2017 Q1 | 385.24 Thousand CAD | 21.04% |
| 2016 Q1 | -11.41 Thousand CAD | 0.0% |
| 2016 Q3 | 94.04 Thousand CAD | 0.0% |
| 2016 Q2 | - CAD | 100.0% |
| 2016 Q4 | 318.27 Thousand CAD | 238.43% |
| 2016 FY | 412.32 Thousand CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 FY | - CAD | 100.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | -195.61 Thousand CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 116.33 Million USD | 23.633% |
| Theratechnologies Inc. | 81.76 Million USD | -8.655% |
| Safety Shot Inc | 202.67 Thousand USD | -43735.247% |
| Cosmos Health Inc. | 53.37 Million USD | -66.441% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 79.934% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 79.489% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -174.975% |
| ProPhase Labs, Inc. | 44.38 Million USD | -100.164% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -597.612% |
| Dynavax Technologies Corporation | 232.28 Million USD | 61.753% |
| Radius Health, Inc. | 2.88 Billion USD | 96.918% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -4506.743% |
| Alvotech | 91.43 Million USD | 2.836% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -268.745% |
| Alpha Teknova, Inc. | 36.68 Million USD | -142.179% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 80.869% |
| SCYNEXIS, Inc. | 140.14 Million USD | 36.606% |
| Harrow Health, Inc. | 130.19 Million USD | 31.762% |
| Biofrontera Inc. | 34.07 Million USD | -160.752% |
| DURECT Corporation | 8.54 Million USD | -939.318% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 85.376% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 81.751% |
| OptiNose, Inc. | 70.98 Million USD | -25.151% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -1264.019% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -75.634% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -124.615% |
| SIGA Technologies, Inc. | 139.91 Million USD | 36.505% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 30.734% |
| Shineco, Inc. | 9.8 Million USD | -806.368% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 91.27% |
| Procaps Group S.A. | 409.92 Million USD | 78.327% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -6723.418% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Viatris Inc. | 15.42 Billion USD | 99.424% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -268.745% |
| Rockwell Medical, Inc. | 83.61 Million USD | -6.254% |
| Incannex Healthcare Limited | 12 Thousand USD | -740240.8% |
| Aytu BioPharma, Inc. | 81 Million USD | -9.677% |
| Tilray Brands, Inc. | 788.94 Million USD | 88.739% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 84.325% |
| PetIQ, Inc. | 1.1 Billion USD | 91.938% |
| Silver Spike Investment Corp. | 11.72 Million USD | -657.89% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 95.292% |
| Journey Medical Corporation | 79.18 Million USD | -12.2% |
| Alimera Sciences, Inc. | 80.75 Million USD | -10.014% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -1425.85% |
| Assertio Holdings, Inc. | 152.06 Million USD | 41.579% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Embecta Corp. | 1.12 Billion USD | 92.073% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -8153.482% |
| Procaps Group, S.A. | 409.92 Million USD | 78.327% |
| PainReform Ltd. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -217.709% |
| Hempacco Co., Inc. | 4.04 Million USD | -2095.968% |
| Talphera, Inc. | 651 Thousand USD | -13546.835% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 86.838% |
| Alvotech | 91.43 Million USD | 2.836% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 93.147% |
| Kamada Ltd. | 144.75 Million USD | 38.628% |
| Indivior PLC | 1.09 Billion USD | 91.872% |
| Currenc Group, Inc. | 53.25 Million USD | -66.821% |
| Evoke Pharma, Inc. | 5.18 Million USD | -1614.867% |
| Flora Growth Corp. | 76.07 Million USD | -16.787% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -8153.482% |
| Evolus, Inc. | 202.08 Million USD | 56.038% |
| HUTCHMED (China) Limited | 837.99 Million USD | 89.398% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 86.213% |
| Akanda Corp. | 2.16 Million USD | -4012.905% |